The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Validation of a Novel Mitochondrial Drug Target for Parkinson’s Disease
Study Rationale: Mitochondria provide cells with energy, but they also help regulate the flow of large amounts of calcium ions that flood neurons when they are active. In Parkinson’s disease (PD)...
-
Research Grant, 2022Development of a Safe and Efficient Method to Treat Parkinson’s Disease Using RNA-based Gene Therapy
Study Rationale: Gene mutations are one of several cause of Parkinson’s disease (PD). Developing an efficient method for introducing functional versions of these mutated genes into cells that are...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction
Study Rationale: Mitochondrial dysfunction in dopamine-producing neurons is one of the hallmarks of Parkinson’s disease (PD) pathology. Inside mitochondria is a protein called Paraoxonase 2 (PON2)...
-
Research Grant, 2022Using the Emergence of New Symptoms as a Measure for Parkinson’s Disease Progression in Clinical Trials
Study Rationale: Studies suggest that as Parkinson’s disease (PD) progresses, new areas of the brain fall prey to PD pathology. If this is the case, PD progression may be best assessed by tracking the...
-
Research Grant, 2022Restoring the Blood-brain Barrier to Prevent Dissemination of Alpha-synuclein and Progression of Parkinson’s Disease
Study Rationale: The cells of the brain are physically separated from the rest of the body by the blood-brain barrier, a network of blood vessels that restricts transfer of materials from the...
-
Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2022Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells
Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.